Neri Paola, Bahlis Nizar J, Paba-Prada Claudia, Richardson Paul
Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.
Cancer Treat Res. 2016;169:169-194. doi: 10.1007/978-3-319-40320-5_10.
Survival outcomes of patients with Multiple Myeloma (MM) have improved over the last decade due to the introduction of novel agents such as the immunomodulatory drugs thalidomide, lenalidomide (Len) and pomalidomide, and the proteasome inhibitors bortezomib (BTZ) and carfilzomib [1, 2]. However, despite these major advances, MM remains largely incurable and almost all patients relapse and require additional therapy [3]. The successful introduction of next generation novel agents including oral proteasome inhibitors, deacetylase inhibitors, and especially monoclonal antibodies as part of immunotherapy promises to further improve outcome.
在过去十年中，由于引入了新型药物，如免疫调节药物沙利度胺、来那度胺（Len）和泊马度胺，以及蛋白酶体抑制剂硼替佐米（BTZ）和卡非佐米，多发性骨髓瘤（MM）患者的生存结果有所改善[1,2]。然而，尽管取得了这些重大进展，MM在很大程度上仍然无法治愈，几乎所有患者都会复发并需要额外治疗[3]。作为免疫疗法一部分的下一代新型药物的成功引入，包括口服蛋白酶体抑制剂、去乙酰化酶抑制剂，尤其是单克隆抗体，有望进一步改善治疗结果。
